Nagpur: Thanks to the Genome Genome Rapid (WGS) sequence carried out by CSIR-NEEI, a global initiative on sharing Avian Influenza and Coronavirus data (GISAID) has issued SARS-COV-2 WGS from 500 positive covid samples.
Data will now be available for scientific diaspora and researchers for further study and understanding.
This initiative helps track new variants of viruses and in developing deeper understanding for timely prevention measures.
Dr.
Krishna Khairnar, scientists and head of the environment of Virology, CSIR-Neer, said that this initiative provides a one-stop solution for the scientific community throughout the world.
“This provides a holistic view of the SARS-COV-2 variant and appears to the scientific diaspora, policy makers and even WHO.
This is supported by many government institutions.
GISAID is a pioneer and has the largest database for SARS-COV-2,” he said.
Furthermore Khairnar said that the genotific supervision of Nagpur will now be available to the world.
“GISAID through the available data interface makes it possible to track and improve warnings for the approaching variant.
Like when the omicron variant is detected in Africa, countries begin to prepare them well in advance Turn off the variant that arises throughout the world.
Genome is a blueprint of all life forms and has access to it providing great insight into dynamics.
Sequencing all genomes that have consistently helped recepted new mutations that might be a concern in the future, “he said.
Meanwhile, neeri lab processes 89 positive covid samples where Omicron Varinat BA.2 is found dominant in the sequencing series of the sixth genome carried out for Nagpur Municipal Corporation.
Samples include positive patients with covid symptoms and asymptomatic starting from 27 to 31 January.
This study shows all 89 samples with omicron variants.
In terms of percentage, Lineage Omicron B.1.1529 was found in a sample of 23.6% while BA.2 was at 76.4%.
Lineage BA.2 has become dominant after mid-January.
BA.2 also found in some ICU patients whose swab samples did not test positively for the failure of genes (SGTF).
SublineAge BA.2 is also referred to as stealth omicron because of passing SGTF and even the latest omisure kit test runs, leaving the entire sequencing genome as the main answer to supervision.
Again, the percentage of the ultimate share of Omicron BA.2 among symptomatic patients is higher than other Omicron lineages.
Of the total BA.2 sample lineage, 29.5% belong to the symptomatic case.
On the other hand, among the total sample omicron B1.1.529, only 14.3% were symptomatic patients.